Effects of diazoxide in multiple sclerosis: A randomized, double-blind phase 2 clinical trial.

ABSTRACT:

Objective

The aim of this study was to test the safety of diazoxide and to search for signs of efficacy in patients with relapsing-remitting multiple sclerosis (RRMS).

Methods

In this multicenter, randomized, placebo-controlled, double-blind trial (treatment allocation was concealed), 102 patients with RRMS were randomized to receive a daily oral dose of diazoxide (0.3 and 4 mg/d) or placebo for 24 weeks (NCT01428726). The primary endpoint was the cumulative number of new T1 gadolinium-enhancing lesions per patient, recorded every 4 weeks from week 4 to week 24. Secondary endpoints included brain MRI variables such as the number of new/enlarging T2 lesions and the percentage brain volume change (PBVC); clinical variables such as the percentage of relapse-free patients, relap

SUBMITTER: Villoslada P 

PROVIDER: S-EPMC4567455 | biostudies-literature | 2015 Oct

REPOSITORIES: biostudies-literature